The SIGMACEPTOR™-N Program
Combating neurological conditions: Alzheimer’s disease, epilepsy, depression and
stroke

ANAVEX’s preclinical data has verified the anti-amnesic and neuroprotective action of sigma-1 receptor ligands in various in vitro systems and validated animal models. In our SIGMACEPTOR™-N program, ANAVEX is taking advantage of these properties to develop new drug candidates for Alzheimer’s disease, epilepsy, depression and stroke.

We have a strong portfolio of discovery and preclinical compounds targeting several Central Nervous System diseases in our pipeline. With additional compounds currently in the discovery stage and expected to enter the pipeline in due course, ANAVEX has numerous options for developing additional drug candidates.

Leading marketed therapies in Alzheimer’s disease work partially through a sigma-1 receptor mechanism.